Company intelligence / Profile preview
Zymedi
Incheon, South Koreazymedi.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Developing ZMA001 mAb targeting KARS1 for PAH and PH-ILD in pre-clinical stage. Also has ZMC001 SM for NASH and ZMC101 SM for colorectal and lung cancer in early development stages.
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularImmunologyOtherOncology
- Modalities
- Monoclonal antibodies (mAb)Small molecules (SM)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Evotec SEYonsei University
Beyond the preview
Go deeper on Zymedi.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zymedi.